Table 3.
Distribution of biomarker outcomes in a 1-month and 3-month follow-up after participants’ initial onboarding.
| Test and outcome | 1-month follow-up (n=48), n (%) | 3-month follow-up (n=48), n (%) | ||||
| Sexually transmitted disease |
|
|
||||
|
|
HIVa |
|
|
|||
|
|
|
Positive | 20 (41.7) | 23 (47.9) | ||
|
|
|
Negative | 28 (58.3) | 25 (52.1) | ||
| Substance use |
|
|
||||
|
|
Amphetamine |
|
|
|||
|
|
|
Positive | 24 (50.0) | 21 (43.8) | ||
|
|
|
Negative | 24 (50.0) | 27 (56.2) | ||
|
|
Methamphetamine |
|
|
|||
|
|
|
Positive | 25 (52.1) | 22 (45.8) | ||
|
|
|
Negative | 23 (47.9) | 26 (54.2) | ||
|
|
THCb |
|
|
|||
|
|
|
Positive | 20 (41.7) | 18 (37.5) | ||
|
|
|
Negative | 28 (58.3) | 30 (62.5) | ||
aHIV: human immunodeficiency virus.
bTHC: tetrahydrocannabinol.